Table 1 STR profiling confirms identity of eIMS cell and xenograft models to patient germline material.

From: CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

 

Germline

Diagnosis cells

Diagnosis xenograft

Relapse cells

Relapse xenograft

D5S818

12

12

12

12

12

D13S317

11, 14

11, 14

11, 14

11, 14

11, 14

D7S820

9, 11

9, 12

9, 12

9, 11

9, 11

D16S539

9, 13

9, 13

9, 13

9, 13

9, 13

vWA

16,17

17

17

17

17

TH01

3, 4, 9

6, 8

6, 8

6, 8

6, 8

Amel

X, Y

X, Y

X, Y

X, Y

X, Y

TPOX

8

8

8

8

8

CSF1PO

10, 11

10, 11

10, 11

10, 11

10, 11

D21S11

29, 31

29, 31

29, 31

29, 31

29, 31

D3S1358

15,16

15, 16

15, 16

15, 16

15, 16, 17

D18S51

14, 17

14, 17

14, 17

14, 17

14, 17

FGA

22, 24

22, 24

22, 24

22, 24

22, 24

Penta E

10, 12

10, 12

10,12

10, 12

10, 12

Penta D

9, 10

9,10

9, 10

9, OL

9, 10

% Match

 

84.9

84.9

84.9

88

  1. eIMS cells derived from patient ascites and xenograft tumours were validated against patient germline DNA derived from peripheral blood by STR profiling at the Garvan Institute for Medical Research or CellBank Australia.
Back to article page